skip to main content
10.1145/3340037.3340070acmotherconferencesArticle/Chapter ViewAbstractPublication PagesicmhiConference Proceedingsconference-collections
research-article

Association Analysis Among Treatment Modalities and Comorbidity for Prostate Cancer

Published: 17 May 2019 Publication History

Abstract

Prostate cancer is a common cancer treated with multi-modality. The combinations of modalities are numerous and complex. Clinical practice guidelines and rules have already been proven in many studies. However, the hypotheses of these studies came from physicians' and experts' experiences and observation. Association analysis, as an importance component of data mining, has been proved to be helpful for us to discover rules from big medical databases. We believe association analysis is able to help us to discover new rules between comorbidities and modalities in subjects of prostate cancer, so that employed it to analyze prostate cancer dataset derived from million people file of NHIRD. We successfully found six rules and rule 1,2,3,5,6 could be well explained with known knowledge and literatures, which were "Young prostate cancer patient who were spared from definite treatment tend to be spared from HT.", "TRUS is associated with younger age group, while TURP is associated with older Age.", "RT is associated with HT.", "CT is highly associated with RT.", "Hemiplegia, cerebrovascular disease, moderate to severe renal disease, diabetes with end organ damage is associated with TURP. Patients with TURP are associated with more comorbidity." We also discovered rule 4: "Younger patients who received HT is highly associated with previous RP.", which are still hypothesis and deserve our validation.

References

[1]
Houston, K.A., et al. 2018. Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013. J. Urol. 199, 3 (Mar. 2018), 676--682.
[2]
Litwin, M.S. and H.J. Tan 2017. The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA, 317, 24 (Jun. 2017), 2532--2542.
[3]
Mohler, J.L., et al. 2014. Prostate cancer, version 2.2014. J. Natl. Compr. Canc. Netw. 12,5 (May 2014), 686--718.
[4]
Nakayama, M., et al. 2018. Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan. Am. J. Mens. Health. 12,4 (Jul. 2018), 1094--1101.
[5]
Rajan, P., et al. 2017. Effect of Comorbidity on Prostate Cancer-Specific Mortality: A Prospective Observational Study. J. Clin. Oncol. 35, 31 (Nov. 2017), 3566--3574.
[6]
Edwards, B.K., et al. 2014. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 120, 9 (May 2014), 1290--314.
[7]
Charlson, M.E., et al. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40,5 (Jan. 1987), 373--83.
[8]
Lee, J.Y., et al. 2014. Impact of Charlson comorbidity index varies by age in patients with prostate cancer treated by radical prostatectomy: a competing risk regression analysis. Ann. Surg. Oncol. 21,2 (Feb. 2014), 677--83.
[9]
Guzzo, T.J., et al. 2010. Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology 76, 3 (Sep. 2010), 553--7.
[10]
Lee, J.Y., et al. 2014. Charlson comorbidity index is an important prognostic factor for long-term survival outcomes in Korean men with prostate cancer after radical prostatectomy. Yonsei Med. J. 55, 2 (Mar. 2014), 316--23.
[11]
Sivaraman, A., et al. 2016. Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy. World J. Urol. 34,10 (Oct. 2016), 1367--72.
[12]
Agrawal, R.; Imieliński, T.; Swami, A. 1993. Mining association rules between sets of items in large databases. Proceedings of the 1993 ACM SIGMOD international conference on Management of data - SIGMOD '93. p. 207. CiteSeerX 10.1.1.40.6984
[13]
Held, F.P., et al. 2016. Association Rules Analysis of Comorbidity and Multimorbidity: The Concord Health and Aging in Men Project. J. Gerontol. A. Biol. Sci. Med. Sci. 71, 5 (May 2016), 625--31.
[14]
Michailidou, K., et al. 2017. Association analysis identifies 65 new breast cancer risk loci. Nature, 551, 7678 (Nov. 2017), 92--94.
[15]
Hsing, A.W. and J.P. Ioannidis 2015. Nationwide Population Science: Lessons From the Taiwan National Health Insurance Research Database. JAMA Intern. Med. 175, 9 (Sep. 2015), 1527--9.
[16]
Cheng, C.L., et al. 2015. Validity of in-hospital mortality data among patients with acute myocardial infarction or stroke in National Health Insurance Research Database in Taiwan. Int. J. Cardiol. 201 (Dec. 2015), 96--101.
[17]
Yee, C.H., et al. 2019. Survey on prevalence of lower urinary tract symptoms in an Asian population. Hong. Kong. Med. J. 25, 1 (Feb. 2019), 13--20.
[18]
{Robert, G., A. de la Taille, and A. 2018. Descazeaud, Surgical treatment of BPO: Standard and innovations. Prog. Urol. 28, 15 (Nov. 2018), 856--867.
[19]
Piccirillo, J.F., et al. 2008. The changing prevalence of comorbidity across the age spectrum. Crit. Rev. Oncol. Hematol. 67, 2 (Aug. 2008), 124--32.
[20]
Valerio, M., et al. 2014. The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur. Urol. 66, 4 (Oct. 2014), 732--51.
[21]
Chade, D.C., et al. 2011. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur. Urol. 60, 2 (Aug. 2011), 205--10.
[22]
Sanderson, K.M., et al. 2006. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J. Urol. 176, 5 (Nov. 2006), 2025-31; discussion 2031-2.

Index Terms

  1. Association Analysis Among Treatment Modalities and Comorbidity for Prostate Cancer

    Recommendations

    Comments

    Information & Contributors

    Information

    Published In

    cover image ACM Other conferences
    ICMHI '19: Proceedings of the 3rd International Conference on Medical and Health Informatics
    May 2019
    207 pages
    ISBN:9781450371995
    DOI:10.1145/3340037
    Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than ACM must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee. Request permissions from [email protected]

    In-Cooperation

    • University of Electronic Science and Technology of China: University of Electronic Science and Technology of China

    Publisher

    Association for Computing Machinery

    New York, NY, United States

    Publication History

    Published: 17 May 2019

    Permissions

    Request permissions for this article.

    Check for updates

    Author Tags

    1. Association analysis
    2. chemotherapy
    3. comorbidity
    4. hormone therapy
    5. prostate cancer
    6. radical prostatectomy
    7. radiotherapy

    Qualifiers

    • Research-article
    • Research
    • Refereed limited

    Conference

    ICMHI 2019

    Contributors

    Other Metrics

    Bibliometrics & Citations

    Bibliometrics

    Article Metrics

    • 0
      Total Citations
    • 50
      Total Downloads
    • Downloads (Last 12 months)0
    • Downloads (Last 6 weeks)0
    Reflects downloads up to 05 Mar 2025

    Other Metrics

    Citations

    View Options

    Login options

    View options

    PDF

    View or Download as a PDF file.

    PDF

    eReader

    View online with eReader.

    eReader

    Figures

    Tables

    Media

    Share

    Share

    Share this Publication link

    Share on social media